Status:
COMPLETED
A Phase II Study in Patients With Alopecia Areata
Lead Sponsor:
Reistone Biopharma Company Limited
Conditions:
Alopecia Areata
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a global Phase 2 study to evaluate the safety and effectiveness of an investigational study drug (called SHR0302) in adults with moderate to severe alopecia areata.
Detailed Description
The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-rangin...
Eligibility Criteria
Inclusion
- Male or female subjects between 18-65 years of age (both inclusive), at the time of informed consent;
- Must have moderate to severe alopecia areata.
Exclusion
- Other types of alopecia or other diseases that can cause hair loss
- Other scalp diseases that could interfere with assessment of hair loss/regrowth
- Any previous use of any Janus kinase (JAK) inhibitor
Key Trial Info
Start Date :
May 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2021
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04346316
Start Date
May 13 2020
End Date
June 29 2021
Last Update
July 16 2021
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Quest Dermatology Research
Northridge, California, United States, 91324
2
Moore Clinical Research
Brandon, Florida, United States, 33511
3
Dawes Fretzin Clinical Research
Indianapolis, Indiana, United States, 46250
4
Skin Search of Rochester, Inc
Rochester, New York, United States, 14623